Encellin fetches $5.9m seed

Encellin, a personalized regenerative medicine biotech company, has secured $5.9 million in seed financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this